Navigation Links
Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
Date:10/29/2009

s will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. Additionally, with respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Paul G. Allen Family Foundation announced today the award ... of researchers with projects at the frontier of one ... human brain cells in the laboratory. The projects are ... years.  "This new cohort of Allen ... the field of neuronal maturation is at the leading ...
(Date:4/30/2015)... - Continued Advancement Toward Goal of ... Shire (LSE: SHP, NASDAQ: SHPG ) announces ... 2015. Financial Highlights Q1 2015 Growth(1) ... $1,488 million +11% +15% Non GAAP operating income $683 ... operations $475 million +55% Non GAAP EBITDA margin (excluding ...
(Date:4/30/2015)... 2015 Available in select spas ... , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield Cream ... while battling the weakening threat of inflammaging, aging ... formulated with star ingredient GLYCOSEA, a complex of ... complex of soothing minerals and trace elements. GLYCOSEA ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Sterlitech ... ultrafiltration membranes, the PX, PY, and PZ ... sheets, and disks. Designed to be ideal ... new membranes can fill critical process requirements where ... downstream processes. , “New regulations on industrial wastewater ...
Breaking Biology Technology:The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 2The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 3The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 4The Paul G. Allen Family Foundation Awards $7.5 Million To Study Brain Cell Growth And Development 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Sterlitech Offers New Ultrafiltration Membranes 2
... , ... The increased need for pharmaceutical packaging companies to reduce waste ... environment has led to an increased demand for specialised deblistering ... machines, called Press-Outs, are used to increase production yields by recovering valuable ...
... PASADENA, Calif., Sept. 23 Alexandria Real Estate Equities, Inc. ... commencing an underwritten public offering of 3,000,000 shares of common ... are acting as joint bookrunning managers in connection with the ... grant the underwriters a thirty-day option to purchase up to ...
... FRANCISCO, September 23 InspireMD, developers of,MGuard(TM), announced today ... MGuard(TM) Registry. MGuard(TM) was successfully implanted in,Natanya, Israel, at ... the principal investigator for the Registry at this hospital. ... will enroll 100 ,real world, MGuard patients,from eight hospitals ...
Cached Biology Technology:Deblistering Device Keeps Production Ahead Of Pack 2Deblistering Device Keeps Production Ahead Of Pack 3Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock 2Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock 3InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 2InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco 3
(Date:3/23/2015)... SoundView Technology Group issues a new research update following the ... wallet. SoundView was one of the selected user groups to provide ... in multiple scenarios and outlets. Soundview shares ... both debit and credit card payments.  Soundview ... meets their plans in 2015, it would push our IV ...
(Date:3/23/2015)... 23, 2015  In the 2014 fiscal year, irs.gov ... losses. This figure accounts for a fraction of the ... Nilson Report, exceeds $11 billion globally. The polygraph has ... crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test in ...
(Date:3/20/2015)... 20, 2015 Research and Markets ... the "India Sensors Market Forecast and Opportunities ... The sensor market is projected to grow at ... Consumer electronics, automotive, industrial and healthcare sectors are ... country. In addition, adoption of MEMS technology in ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... cheaper, more effective liver cancer treatment, reports Lisa Richards ... over 2,800 people in the UK each year, of ... Surgery is the best option, but is unsuitable for ... chemotherapy. The American Cancer Society estimates that 18,510 new ...
... heredity ?are bad: The more mutations in the cell's DNA, the ... years it has become clear that the very processes that generate ... actually protect us from cancer. How does the body know how ... out of control, causing a sharp rise in our cancer risk? ...
... many years of growth before a tree is ready to ... scientists at universities in Sweden and the United States have ... In the annual plant Arabidopsis, the first plant to have ... T (FT) induce flowering in response to day length. It ...
Cached Biology News:Weizmann Institute scientists discover a molecular security mechanism for keeping mutations in check 2Weizmann Institute scientists discover a molecular security mechanism for keeping mutations in check 3Scientists discover that ancient genes dictate flowering, fall bud set 2
...
... Lyophilized from 2 mM sodium phosphate buffer, ... Cathepsin D is a major lysosomal aspartyl ... 52 kDa proenzyme. Overexpression of cathepsin D ... higher risk of relapse and metastasis. Cathepsin ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
Biology Products: